Joel Raffel1, Ruth Dobson2, Arie Gafson2, Miriam Mattoscio3, Paolo Muraro3, Gavin Giovannoni2. 1. Queen Mary University of London, Blizard Institute, Barts and the London School of Medicine and Dentistry, UK. Electronic address: joelraffel@doctors.org.uk. 2. Queen Mary University of London, Blizard Institute, Barts and the London School of Medicine and Dentistry, UK. 3. Department of Medicine, Division of Brain Sciences, Centre for Neuroscience, Wolfson Neuroscience Laboratories, Imperial College, London, UK.
Abstract
BACKGROUND: Anti-Epstein-Barr virus (EBV) nuclear antigen-1 (anti-EBNA-1) IgG antibody titres have been found to correlate with MRI and clinical measures of disease activity in MS. Despite being a putative biomarker of disease activity, the effect of disease modifying drugs on anti-EBNA-1 IgG titre has not yet been determined. METHODS: In this study, we investigated the effect of interferon-beta and natalizumab therapy on prospective sera anti-EBNA-1 IgG titres, using a quantitative ELISA, in patients with relapsing-remitting MS. RESULTS: For both the interferon-beta and natalizumab group, there was no significant difference between pre-therapy and post-therapy anti-EBNA-1 IgG titre. There was also no significant difference between the groups with regard to mean percentage change in anti-EBNA-1 IgG titre over 12 months of treatment. CONCLUSIONS: This study suggests that anti-EBNA-1 IgG titre is unlikely to be a good surrogate marker for disease activity in patients on disease modifying drugs.
BACKGROUND: Anti-Epstein-Barr virus (EBV) nuclear antigen-1 (anti-EBNA-1) IgG antibody titres have been found to correlate with MRI and clinical measures of disease activity in MS. Despite being a putative biomarker of disease activity, the effect of disease modifying drugs on anti-EBNA-1 IgG titre has not yet been determined. METHODS: In this study, we investigated the effect of interferon-beta and natalizumab therapy on prospective sera anti-EBNA-1 IgG titres, using a quantitative ELISA, in patients with relapsing-remitting MS. RESULTS: For both the interferon-beta and natalizumab group, there was no significant difference between pre-therapy and post-therapy anti-EBNA-1 IgG titre. There was also no significant difference between the groups with regard to mean percentage change in anti-EBNA-1 IgG titre over 12 months of treatment. CONCLUSIONS: This study suggests that anti-EBNA-1 IgG titre is unlikely to be a good surrogate marker for disease activity in patients on disease modifying drugs.
Authors: Linn Persson Berg; Marcus Eriksson; Sonia Longhi; Ingrid Kockum; Clemens Warnke; Elisabeth Thomsson; Malin Bäckström; Tomas Olsson; Anna Fogdell-Hahn; Tomas Bergström Journal: BMJ Neurol Open Date: 2022-07-27
Authors: María Inmaculada Domínguez-Mozo; Lorena López-Lozano; Silvia Pérez-Pérez; Ángel García-Martínez; María José Torrejón; Rafael Arroyo; Roberto Álvarez-Lafuente Journal: Front Immunol Date: 2022-09-14 Impact factor: 8.786